Couldn’t attend this year’s Cell & Gene Therapies State of the Industry Briefing in-person or looking to have a copy of the slides to reference again? View the full webcast below and download the 2018 Industry Update PPT presentation.
To see all three of the video options click on the horizontal bars in the upper left corner.
Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine
Robert Preti, Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector
Robert Preti, Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector (chair)
Bob Azelby, EVP, Chief Commercial Officer, Juno Therapeutics
Manuel Litchman, President, CEO and Director, Mustang Bio
James Noble, CEO, Adaptimmune
Pascal Touchon, SVP and Global Head, Cell and Gene, Novartis Oncology
Scott Wolchko, President and CEO, Fate Therapeutics
Martha Rook, Head of Gene Editing and Novel Modalities, MilliporeSigma (chair)
Bill Lundberg, CSO, CRISPR Therapeutics
Sandy Macrae, President and CEO, Sangamo Therapeutics
Geoff Nichol, SVP, Global Clinical Development and CMO, BioMarin Pharmaceutical
Amber Salzman, President and CEO, Adverum Biotechnologies
Deepak Srivastava, President, Gladstone Institutes; Professor, UC San Francisco
End of program.
55 Cyril Magnin St.
San Francisco, CA 94102
Over 500 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
